ATXS News and Press, Astria Therapeutics Inc. From 10/11/23

Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, tod...

2023-10-11 17:47:34 ET More on Astria TherapeuticS Astria Therapeutics: Too Much Baggage, Too Strong A Competition Astria wins FDA fast track tag for lead candidate Seeking Alpha’s Quant Rating on Astria TherapeuticS Historical earnings data for Astria...

-- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis – -- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a b...

2023-09-19 08:00:00 ET Summary Astria Therapeutics (formerly Catabasis Pharma) has raised $100 million and acquired Quellis to develop STAR-0215, a plasma kallikrein inhibitor for hereditary angioedema (HAE). STAR-0215 has a longer half-life than existing HAE treatments, potential...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that preclinical data supporting STAR-0215&#x...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information regarding pa...

2023-08-07 17:08:13 ET Astria TherapeuticS press release ( NASDAQ: ATXS ): Q2 GAAP EPS of -$0.45 beats by $0.04 . As of June 30, 2023, Astria had cash, cash equivalents and short-term investments of $203.0 million, compared to $226.4 million as of December 31, 2022. ...

-- STAR-0215 Granted Fast Track Designation by the U.S. FDA -- -- New Results from Healthy Subjects Informing STAR-0215 Administration Plan Expected in Q4 2023 -- -- ALPHA-STAR on Track with Initial Proof-of-Concept Results in Patients Anticipated Mid-2024 -- Astria Th...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 174,000 shares of Astria’s...

-- On Track for Proof-of-Concept Results in HAE Patients in Mid-2024 -- -- Results To-Date Support STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing...